1-9 of 9
Peter Wood
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis

Katharine L Lewis, FRCPath, MRCP, MBBS, Kate Manos, MBBS, John Casey, FRACP,FRCPA,MBBS, Julie Crawford, MDMBBS,FRACP, Shir-Jing Ho, FRACP,FRCPA,MBBS, Samar Issa, FRACP, Andrew Grigg, Peter Wood, Maher K. Gandhi, PhD, Eliza A Hawkes, Chan Y. Cheah
Journal: Blood
Blood (2019) 134 (Supplement_1): 1620.
https://doi.org/10.1182/blood-2019-125730
Published: 2019
Journal Articles

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

Brad S Kahl, MD, John M. Burke, MD, Richard van der Jagt, MD FRCPC, Julie Chang, MD, Peter Wood, Tim Hawkins, FRACP, FRCPA, David MacDonald, Judith Trotman, MBChB, FRACP, FRCPA, David Simpson, MBChB, Kathryn S. Kolibaba, MD, Samar Issa, FRACP, Doreen Hallman, Ling Chen, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 484.
https://doi.org/10.1182/blood.V130.Suppl_1.484.484
Published: 2017
Journal Articles

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Constantine S. Tam, MBBS, Judith Trotman, MBChB, Stephen Opat, MD, Paula Marlton, MBBS, Gavin Cull, MBBS DM FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Matthew Ku, MBBS, David Ritchie, MD PhD, Emma Verner, FRACP, FRCPA, MBBS, Sumita Ratnasingam, MBBS, Mary Ann Anderson, MBBS, Peter Wood, MD FRACP, FRCPA, MBBS, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts
Journal: Blood
Blood (2016) 128 (22): 1216.
https://doi.org/10.1182/blood.V128.22.1216.1216
Published: 2016
Journal Articles

The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL)

Colm Keane, MB BCh BAO MSc MBA MRCPI FRCPath FRCPA PhD, Kimberly Jones, PhD, Clare Gould, MBBS, David Hamm, Peter Wood, MD FRACP, FRCPA, MBBS, Simone Birch, FRCPA PhD, Pauline Crooks, BSc, Michael R Green, PhD, Dipti Taulaulikar, MBBS, PhD FRACP, FRCPA,, Sanjiv Jain, FRCPA, Josh Tobin, MBBS, Maher K Gandhi, PhDFRACP FRCPath FRCP
Journal: Blood
Blood (2015) 126 (23): 3893.
https://doi.org/10.1182/blood.V126.23.3893.3893
Published: 2015
Journal Articles

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Clinical Trials & Observations
Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu-Lam Kwan, David Simpson, Michael Craig, Kathryn Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela Munteanu, Ling Chen, John M. Burke
Journal: Blood
Blood (2014) 123 (19): 2944–2952.
https://doi.org/10.1182/blood-2013-11-531327
Published: 2014
Includes: Supplemental data
Journal Articles

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

Ian W. Flinn, MD, PhD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, John M. Burke, MD
Journal: Blood
Blood (2012) 120 (21): 902.
https://doi.org/10.1182/blood.V120.21.902.902
Published: 2012
Journal Articles

Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

John M. Burke, MD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Richard E. White, PhD, MPH, MBE, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, Ian W. Flinn, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 155.
https://doi.org/10.1182/blood.V120.21.155.155
Published: 2012
Journal Articles

Dissimilar Respiratory and Hemodynamic Responses In TRALI Induced by Stored Red Cells and Whole Blood Platelets.

John-Paul Tung, John F Fraser, Maria Nataatmadja, Adrian G Barnett, Kathryn I Colebourne, Kristen M Glenister, Anna Y Zhou, Peter Wood, Christopher C Silliman, MD/PhD, Yoke Lin Fung
Journal: Blood
Blood (2010) 116 (21): 1112.
https://doi.org/10.1182/blood.V116.21.1112.1112
Published: 2010
Journal Articles

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

Clinical Trials & Observations
Elizabeth A. Sconce, Tayyaba I. Khan, Hilary A. Wynne, Peter Avery, Louise Monkhouse, Barry P. King, Peter Wood, Patrick Kesteven, Ann K. Daly, Farhad Kamali
Journal: Blood
Blood (2005) 106 (7): 2329–2333.
https://doi.org/10.1182/blood-2005-03-1108
Published: 2005